DAM
SYRE icon

Deltec Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Deltec Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-999
Closed -$192K – 192
2019
Q3 		$192K Sell
999
-916
-48% -$178K 0.05% 151
2019
Q2 		$328K Buy
1,915
+384
+25% +$66.4K 0.07% 139
2019
Q1 		$308K Hold
1,531
– – 0.07% 134
2018
Q4 		$287K Sell
1,531
-2,073
-58% -$440K 0.08% 124
2018
Q3 		$862K Sell
3,604
-2,467
-41% -$576K 0.17% 103
2018
Q2 		$1.61M Buy
+6,071
New +$1.49M 0.32% 67

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deltec Asset Management's SYRE Position: Q4 2019 in Review

Deltec Asset Management sold out of Spyre Therapeutics (SYRE) in Q4 2019, closing a stake of 999 shares — an estimated $192K sold.

Deltec Asset Management first reported a position in SYRE in Q2 2018 and held it in 6 quarters. The position peaked at $1.61M in Q2 2018. 68 funds tracked by Wall St. Rank hold SYRE as of Q4 2019.

  • Deltec Asset Management reported no remaining Spyre Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Deltec Asset Management sold 999 Spyre Therapeutics shares in Q4 2019, an estimated $192K.
  • Deltec Asset Management first reported a position in Spyre Therapeutics in Q2 2018 and held it in 6 quarters.
  • Deltec Asset Management's Spyre Therapeutics position peaked at $1.61M in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2019.

Based on Deltec Asset Management's 13F filing for Q4 2019, filed 27 Jan 2020.